For people with serious heart disease who are already taking cholesterol-lowering pills, adding one of two special drugs (evolocumab or alirocumab) can lower their chances of having a major heart...

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects

Narrative Review

In Vitro

2020

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects

Score: 1

DOI: 10.3389/fphys.2020.595819

Similar Assertions

Adding a drug called evolocumab to cholesterol-lowering statins can lower the chances of serious heart problems by 20% in people who already have heart disease.

92%

For people with heart disease who are already taking cholesterol-lowering statins but still have high LDL, adding a drug called evolocumab can lower their chances of having a heart attack, stroke, or other serious heart problems by about 15% over two years.

89%

For people with heart disease who are already taking cholesterol-lowering drugs, adding a medicine called evolocumab can lower their chance of having a heart attack, stroke, or other serious heart problems by about 15% over two years.

88%

Adding a drug called evolocumab to cholesterol-lowering statins can lower the chances of serious heart problems by 20% in people who already have heart disease.

88%

For people with clogged arteries who are already on cholesterol drugs, adding a medicine called evolocumab helps lower their risk of heart problems — and it works pretty well even for those who've had a stroke before, though the benefit might be a bit smaller for them.

87%